Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BPR202202

CD37+CD22 CAR-T

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: CD37+CD22 CAR-T
    Indications: AML
    Research phase: PCC
    Cooperation demands: License-out or co-development
  • Highlights

    1. Clear MoA.


    (1). CD37 is expressed on mature B cells, but it expressed at very low levels in T cells, macrophages, monocytes and dendritic cells.
    (2). CD22 is expressed high in mature B cells and most B cell malignancies, including B-ALL(>90% ), NHL, and HCL.
    (3). CD22 is not only a specific antigen target on the surface of many B cell malignancies, but also has endocytosis and internalization properties.


    2. High affinity antibodies.


    3. High efficacy in-vitro.


    (1). High cell killing activity


    High cell killing activity


    (2). High cytokine production


    High cytokine production


    4. CD37+CD22 CAR-T Significantly prolonged survival in tumor-bearing mice.


    CD37+CD22 CAR-T Significantly prolonged survival in tumor-bearing mice

  • Project Introduction

    1. Asset type: CD22 + CD37 CAR-T

    2. Indication: Hematological malignancies (leukemia, multiple myeloma, lymphoma)

    3. Research phase: PCC

    4. Cooperation demands: License-out or co-development

    5. Research progress:
    1) Complete the CD37+CD22 CAR-T Screening.
    2) CD37+CD22 CAR-T activity in vitro showed the high killing activity against many CD37, CD20, CD22 positive cancer cells.
    3) CD37+CD22 CAR-T significantly prolonged the survival of tumor-bearing mice. After 50 days treatment, no mice died.

Comments (0)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message